Product Description
Fields of Application:
Diabetes II
Active Substance:
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog. As GLP-1, liraglutide induces insulin secretion from β-cells by binding to GLP receptors in the pancreas.
Liraglutide is
AI Product Description
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Liraglutide is a <strong>GLP-1 receptor agonist</strong> synthesized via solid-phase peptide synthesis. It mimics human glucagon-like peptide-1 to regulate glucose metabolism. Molecular Formula: <strong>C204H316N54O60S</strong>; CAS No.: <strong>204656-20-2</strong>.</p>
<h3>Application</h3>
<ul>
<li><strong>Pharmaceutical Manufacturing</strong>: Production of injectable formulations for Type 2 Diabetes management.</li>
<li><strong>Obesity Treatment</strong>: Development of weight-loss therapies targeting appetite suppression.</li>
<li><strong>Research & Development</strong>: Supply for clinical trials investigating metabolic syndrome mechanisms.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated in patients with personal or family history of medullary thyroid carcinoma. Must be stored at <strong>2°C to 8°C</strong> in original packaging. Strict adherence to sterile handling protocols is required during industrial processing.</p>